CTLA4 and neoplasm: Most recently, novel immunotherapies, in particular checkpoint inhibition with anti-CTLA-4 and anti-PD-1/-PD-1L antibodies targeting negative regulatory receptors on T cells, have been successfully applied against a growing number of tumor types [8].